306 related articles for article (PubMed ID: 31931812)
1. Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential.
Ma L; Zhu M; Gai J; Li G; Chang Q; Qiao P; Cao L; Chen W; Zhang S; Wan Y
J Nanobiotechnology; 2020 Jan; 18(1):12. PubMed ID: 31931812
[TBL] [Abstract][Full Text] [Related]
2. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
3. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
[TBL] [Abstract][Full Text] [Related]
4. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
[TBL] [Abstract][Full Text] [Related]
5. Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody.
Seckinger A; Buatois V; Moine V; Daubeuf B; Richard F; Chatel L; Viandier A; Bosson N; Rousset E; Masternak K; Salgado-Pires S; Batista C; Mougin C; Juan-Bégeot F; Poitevin Y; Hose D
Front Immunol; 2024; 15():1378813. PubMed ID: 38720892
[TBL] [Abstract][Full Text] [Related]
6. Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.
Weiskopf K; Anderson KL; Ito D; Schnorr PJ; Tomiyasu H; Ring AM; Bloink K; Efe J; Rue S; Lowery D; Barkal A; Prohaska S; McKenna KM; Cornax I; O'Brien TD; O'Sullivan MG; Weissman IL; Modiano JF
Cancer Immunol Res; 2016 Dec; 4(12):1072-1087. PubMed ID: 27856424
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
8. Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein
Wang Z; Hu N; Li X; Wang H; Ren C; Qiao C; Chen G; Wang J; Zhou L; Wu J; Zhang D; Feng J; Shen B; Peng H; Luo L
Mol Pharmacol; 2021 Sep; 100(3):193-202. PubMed ID: 34315811
[TBL] [Abstract][Full Text] [Related]
9. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
[TBL] [Abstract][Full Text] [Related]
10. CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma.
Zhu D; Hadjivassiliou H; Jennings C; Mikolon D; Ammirante M; Acharya S; Lloyd J; Abbasian M; Narla RK; Piccotti JR; Stamp K; Cho H; Hariharan K
MAbs; 2024; 16(1):2310248. PubMed ID: 38349008
[TBL] [Abstract][Full Text] [Related]
11. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
[TBL] [Abstract][Full Text] [Related]
12. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
He Y; Helfrich W; Bremer E
Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
[TBL] [Abstract][Full Text] [Related]
13. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.
Sim J; Sockolosky JT; Sangalang E; Izquierdo S; Pedersen D; Harriman W; Wibowo AS; Carter J; Madan A; Doyle L; Harrabi O; Kauder SE; Chen A; Kuo TC; Wan H; Pons J
MAbs; 2019; 11(6):1036-1052. PubMed ID: 31257988
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
15. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer.
Zeng D; Sun Q; Chen A; Fan J; Yang X; Xu L; Du P; Qiu W; Zhang W; Wang S; Sun Z
Oncotarget; 2016 Dec; 7(50):83040-83050. PubMed ID: 27863402
[TBL] [Abstract][Full Text] [Related]
16. Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.
Russ A; Hua AB; Montfort WR; Rahman B; Riaz IB; Khalid MU; Carew JS; Nawrocki ST; Persky D; Anwer F
Blood Rev; 2018 Nov; 32(6):480-489. PubMed ID: 29709247
[TBL] [Abstract][Full Text] [Related]
17. Localized CD47 blockade enhances immunotherapy for murine melanoma.
Ingram JR; Blomberg OS; Sockolosky JT; Ali L; Schmidt FI; Pishesha N; Espinosa C; Dougan SK; Garcia KC; Ploegh HL; Dougan M
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10184-10189. PubMed ID: 28874561
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
[TBL] [Abstract][Full Text] [Related]
19. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.
Dheilly E; Moine V; Broyer L; Salgado-Pires S; Johnson Z; Papaioannou A; Cons L; Calloud S; Majocchi S; Nelson R; Rousseau F; Ferlin W; Kosco-Vilbois M; Fischer N; Masternak K
Mol Ther; 2017 Feb; 25(2):523-533. PubMed ID: 28153099
[TBL] [Abstract][Full Text] [Related]
20. The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a.
Peluso MO; Adam A; Armet CM; Zhang L; O'Connor RW; Lee BH; Lake AC; Normant E; Chappel SC; Hill JA; Palombella VJ; Holland PM; Paterson AM
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
